Information Provided By: 
Fly News Breaks for April 25, 2016
TROV
Apr 25, 2016 | 11:01 EDT
As previously reported, Piper Jaffray downgraded Trovagene to Neutral from Overweight, as analyst William Quirk believes the departure of Chief Commercialization Officer Matt Posard create more uncertainty about the firm's estimates for the company. The analyst, who said he is "yet to cover a company with internal strife that consistently beat numbers," still has an $8 price target on Trovagene shares, which are down 15% to $5.26 in morning trading.
News For TROV From the Last 2 Days
There are no results for your query TROV
